On November 24, 2020 Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, reported that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology (SNO2020 Virtual Conference) (Press release, Midatech Pharma, NOV 24, 2020, View Source [SID1234571649]). Links to the Abstracts and Posters are provided below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PNOC015: An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with External Beam Radiation Therapy (ABSTRACT DDRE-21) – Lead Author: Dr Sabine Mueller, Pacific Pediatric Neuro-Oncology Consortium
The Abstract may be found at:
The Poster may be found at:
Efficacy of Soluble Panobinostat (MTX110) in Preclinical Models of Adult Glioblastoma (ABSTRACT TMOD-27) – Lead Author: Dr David Ashley, Preston Tisch Brain Tumor Centre, Duke University, Durham NC 27710
The Abstract may be found at:
The Poster may be found at:
Commenting, Steve Damment, EVP R&D of Midatech, said: "These presentations provide further information on the encouraging Phase I DIPG trial results recently announced by Midatech on 19 October 2020, and preclinical efficacy data supporting the potential utility of MTX110 for the significantly larger adult glioblastoma indication."
About MTX110
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient’s tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).